TSE:GEN

GeneNews (GEN) Stock Price, News & Analysis

C$0.15
+0.01 (+7.14%)
(As of 06/25/2019)
Today's Range
C$0.14
C$0.15
50-Day Range
C$0.15
C$0.15
52-Week Range
C$0.03
C$0.21
Volume
473,147 shs
Average Volume
1.48 million shs
Market Capitalization
C$25.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GEN stock logo

About GeneNews Stock (TSE:GEN)

GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.

GEN Stock Price History

GEN Stock News Headlines

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Oncology Molecular Diagnostics Market by 2031
Biotech Stock Mailbag: GenVec
StageZero Life Sciences Ltd (SZLS)
See More Headlines
Receive GEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeneNews and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
15
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$234,592.00
Cash Flow
C$0.00 per share
Book Value
C($0.06) per share

Miscellaneous

Free Float
N/A
Market Cap
C$25.49 million
Optionable
Not Optionable
Beta
N/A
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. James R. Howard-Tripp
    Exec. Chairman & CEO
  • Ms. Joanna M. Halsey Esq.
    Gen. Counsel, Chief Compliance Officer & HR Director of IDL
  • Prof. Choong-Chin Liew Ph.D.
    Co-Founder
  • Mr. Warren Whitehead (Age 67)
    Chief Accountant
  • Mr. David Suria
    Sr. Scientist

GEN Stock Analysis - Frequently Asked Questions

How have GEN shares performed in 2024?

GeneNews' stock was trading at C$0.15 at the beginning of 2024. Since then, GEN shares have increased by 0.0% and is now trading at C$0.15.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of GeneNews own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GeneNews investors own include StorageVault Canada (SVI), American Airlines Group (AAL), Aareal Bank (ARL), Broadcom (AVGO), Aspen Technology (AZPN), British American Tobacco (BATS), Cronos Group (CRON) and Edwards Lifesciences (EW).

How do I buy shares of GeneNews?

Shares of GEN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:GEN) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners